UniQure extends eye-watering rally ahead of planned $200 mln share offering

** U.S.-listed shares of Dutch drugmaker UniQure NV QURE.O up another 6.4% to $50.55 on Thurs, a day after its stock rocketed

** QURE shares on the session rise as much as 15.7% to $54.98, highest since Jun 2021

** Shares on Weds finished up ~248% at $47.50 after co said its experimental gene therapy significantly slowed Huntington's disease progression in an early-to-mid-stage trial

** It also announced securing a $175 mln loan from Hercules Capital HTGC.N

** After the bell Weds, co commenced $200 mln share offering, including pre-funded warrants

** It plans to use net proceeds to fund potential commercial launch of AMT-130, and development of its other clinical product candidates, per the offering prospectus

** Leerink Partners, Stifel, Van Lanschot Kempen and Guggenheim Secs are bookrunners for the offering

** QURE has ~54.9 mln shares outstanding for about $2.6 bln current market cap through Weds

** Short interest in QURE shares had nearly tripled from beginning of 2025 to about 9.7 mln shares in mid-Aug. As of Sept 25, about 8.3 mln shares were sold short, ~16% of the public float, per LSEG data